Abstract | BACKGROUND: DESIGN AND METHODS: RESULTS: Among 37 patients enrolled (median age, 29 years; range 8-57 years), 32 patients responded to rituximab with 8 complete and 24 partial responses. Twenty-one patients maintained their response for 1 year, so their steroid treatment was discontinued or its dose reduced (21/37, or 56.8%), and their scores representing quality of life were improved although these changes were not statistically significant. The responses were better for clinical manifestations of the skin, oral cavity and musculoskeletal system (response rate, 71.4-100%) than for other organs. However, infectious complications and primary disease relapse accounted for the majority of treatment failure. The pre-treatment serum level of B cell-activating factor of the tumor necrosis factor family was not associated with better treatment outcome (P=0.147). CONCLUSIONS:
|
Authors | Seok Jin Kim, Jong Wook Lee, Chul Won Jung, Chang Ki Min, Bin Cho, Ho Jin Shin, Joo Seop Chung, Hawk Kim, Won Sik Lee, Young Don Joo, Deok-Hwan Yang, Hoon Kook, Hyoung Jin Kang, Hyo Seop Ahn, Sung-Soo Yoon, Sang Kyun Sohn, Yoo Hong Min, Woo-Sung Min, Hee-Sook Park, Jong Ho Won |
Journal | Haematologica
(Haematologica)
Vol. 95
Issue 11
Pg. 1935-42
(Nov 2010)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 20663943
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- B-Cell Activating Factor
- Immunologic Factors
- Steroids
- Rituximab
|
Topics |
- Adolescent
- Adult
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage)
- B-Cell Activating Factor
(blood)
- B-Lymphocytes
(metabolism)
- Chemical and Drug Induced Liver Injury
(blood, therapy)
- Child
- Chronic Disease
- Diabetes Mellitus
(blood, therapy)
- Female
- Graft vs Host Disease
(blood, drug therapy, metabolism)
- Hematologic Neoplasms
(blood, therapy)
- Humans
- Immunologic Factors
(administration & dosage)
- Male
- Middle Aged
- Prospective Studies
- Rituximab
- Stem Cell Transplantation
- Steroids
(therapeutic use)
- Transplantation, Homologous
- Tuberculosis
(blood, therapy)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|